Document is current

Any future updates will be listed below

Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations

Crossref DOI link: https://doi.org/10.1007/s00044-022-02952-5

Published Online: 2022-09-01

Published Print: 2022-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark